Fox Chase Cancer Center

(redirected from Fox chase cancer)
An institute established in 1904 near Philadephia dedicated to diagnosing and treating cancer, and research into its mechanisms; it is the 4th largest—100 inpatient beds—cancer center in the US
Mentioned in ?
References in periodicals archive ?
M2 EQUITYBITES-November 30, 2015-Accutest Research collaborates with Fox Chase Cancer Center - Temple Health
M2 PHARMA-November 30, 2015-Accutest Research collaborates with Fox Chase Cancer Center - Temple Health
Fox Chase Cancer Center, Philadelphia: In-network for the two dominant carriers.
has entered into a partnership with the Genomics Core Facility of Fox Chase Cancer Center.
Two of Polaris's clients, Fox Chase Cancer Center and the Virtua Fox Chase Cancer Center Program, are already taking advantage of Polaris Oncology's enhanced capabilities to alert care teams to any immediate needs a patient may have.
Washington, Apr 10 ( ANI ): Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the growth in the number of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.
a leading provider of molecular interpretation and therapeutic strategies for personalized cancer care, today announced a partnership with Fox Chase Cancer Center in Philadelphia, to provide molecular interpretation and treatment strategy analysis for genome sequencing and testing provided to advanced stage cancer patients through the Cancer Genome Institute at Fox Chase.
Now, researchers at Fox Chase Cancer Center find that poor psychosocial functioning is associated with VEGF, a signaling protein that not only stimulates tumor growth, but is also associated with shorter disease free survival in head and neck cancer patients,a private news channel reported.
Joshua Meyer, a radiation oncologist at Fox Chase Cancer Center, analyzed trends in U.
Researchers at Fox Chase Cancer Center in Philadelphia have discovered that low-oxygen regions in prostate tumors can be used to predict a rise in PSA levels, a marker of tumor recurrence in prostate cancer.
Bureau of Labor Statistics; tanning Fox Chase Cancer Center, Philadelphia, Bo: The Washington Post; Find Mapman: Jim McMahon
Richard Bleicher of the Fox Chase Cancer Center in Philadelphia, who presented his findings at the American Society of Clinical Oncology's Breast Cancer Symposium in Washington.